Enhanced treatment of liver carcinoma with a drug-eluting hydrogel

Scientists from the Terasaki Institute for Biomedical Innovation (TIBI) have developed an injectable or catheter-administered hydrogel with enhanced capabilities for treating hepatocellular carcinoma (HCC), a deadly form of liver cancer. As described in their recent publication in Advanced Functional Materials, this drug-eluting hydrogel can provide sustained, pH-dependent drug co-delivery and has capabilities for promoting anti-tumor immune responses. This reduces tumor cell proliferation and growth and offers a more efficient means of enabling tumor cell death.